GlaxoSmithKline Pharmaceuticals has approved an investment of ₹1.74 crores in a solar power project for its Nashik plant, utilizing a group captive mechanism. The company also announced its unaudited standalone and consolidated financial results for Q2 2025, showing a revenue from operations of ₹97,363 lakhs. The Board of Directors approved these results in a meeting held on November 6, 2025.
Solar Power Investment
GlaxoSmithKline Pharmaceuticals has approved an investment of ₹1.74 crores for a solar power project at its Nashik plant. The project will operate under a group captive mechanism, furthering the company’s commitment to renewable energy. This initiative involves partnering with Clean Max Galapagos Private Limited to supply 4.95 MWp capacity to meet renewable energy requirements in Maharashtra. Clean Max Galapagos Private Limited, incorporated on May 21, 2024, is set to provide renewable energy to GlaxoSmithKline Pharmaceuticals.
Q2 2025 Financial Performance (Standalone)
The company’s standalone financial results for the quarter ended September 30, 2025, reveal the following:
- Revenue from operations: ₹97,363 lakhs
- Total Income: ₹100,490 lakhs
- Profit before tax: ₹35,065 lakhs
- Profit for the period: ₹25,500 lakhs
Q2 2025 Financial Performance (Consolidated)
The consolidated financial results for the quarter ended September 30, 2025, show:
- Revenue from operations: ₹97,994 lakhs
- Total Income: ₹101,351 lakhs
- Profit before tax: ₹35,400 lakhs
- Profit for the period: ₹25,749 lakhs
The results were approved by the Board of Directors on November 6, 2025.
Source: BSE
